Shulov Innovative Science Ltd. (S.I.S) was founded in 1985 by the late Prof. Aharon Shulov and Aviv Marx. The two joined their unique skills to promote the development of a new analgesic based on a natural snake venom component.
Aharon Shulov. was a professor at the Hebrew University of Jerusalem and a world renown expert in the field of animal venoms. Aviv Marx. is an entrepreneur and a businessman from the Israeli city of Rehovot.
In 1984 Dr. Naftali Primor, Ph.D., a specialist in snake venom chemistry was recruited.
A facility for snake venom production was established in Rehovot.
Proof of Concept
In order to prove the scientific concept that the snake venom contains an analgesic component, several snake venoms were fractionated with accordance to their molecular size.
Those fractions were tested for toxicity by injection in mice and for analgesic properties by a topical application in rodents.
The results clearly demonstrated that the toxicity and the analgesic effect have indeed derived from different, unique and distinct components within the venom.
Identification of the analgesic fraction.
Snake venom consists of more than 1000 different components.
Our aim was to purify, to analyze and to synthetize the analgesic molecules.
Using various analytical methods, the molecular structure of the snake venom analgesic element was elucidated. These fractions include 3-4 amino acids, classifying them as short peptides.
Advanced clinical stage biopharmaceutical company
In 2001 S.I.S established an early-stage bio-pharmaceutical company that focused on the development, manufacturing and testing of novel pharmaceutical New Chemical Entities (NCE’s), based on natural compounds found in rattlesnake venom, towards advanced commercialization.
Currently, SIS is an advanced clinical stage biopharmaceutical company focusing on development of NCE’s for therapeutic uses in dermatology as anti-viral, anti-inflammatory and analgesic agents. The NCE’s are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess unique biological activity and potent therapeutic use for a wide range of clinical indications.
SIS has a comprehensive CMC (Chemistry, Manufacturing, Control) package for the lead molecule API (Active Pharmaceutical Ingredient) ZEP-3.
The company recently completed a Phase II clinical study in Herpes Labialis (Cold sores) – See the “Clinical Trials” section for a detailed report.
SIS will approach the FDA for a pre-IND meeting during Q1 of 2019 to secure an IND submission for an advanced Phase II clinical trial in Herpes Labialis patients in the US, as the next step towards regulatory approval for marketing and commercialization.
In parallel, the company is planning a Phase II clinical study in Atopic Dermatitis (AD), a common dermatological disorder, in Q2 of 2019.
T: +972 8 9314114
F: +972 8 9471062
10 Oppenheimer St.
Science Park, Rehovot,
Get in touch